Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative brain disorder that is characterized by the deposition of amyloid-β protein (Aβ) and neurofibrillary aggregates (tau). There is currently no cure for AD; however, early diagnosis and intervention may prevent progression to dementia. In addition to CSF and blood biomarkers, imaging techniques, such as PET, fMRI, volumetric MRI, and chemical exchange saturation transfer (CEST), have facilitated the early diagnosis of AD and provided essential information about the pathophysiology of AD. Indeed, CEST findings have helped clarify important aspects of the pathophysiology underlying AD. In this article we provide an in-depth review of different CEST applications, including endogenous CEST (APT, creatine-CEST, and glutamate-CEST) and exogenous CEST (angiopep2, glucose, and glymphatic system-related CEST), in further elucidating the pathophysiology of AD and discuss the potential of novel approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
